

Edited by

Daniel A. Erlanson and Wolfgang Jahnke


Fragment-based Drug Discovery

Lessons and Outlook

Volume 67

Series Editors:

R. Mannhold, H. Kubinyi,
G. Folkers



Edited by
Daniel A. Erlanson and
Wolfgang Jahnke

**Fragment-based Drug
Discovery**

Methods and Principles in Medicinal Chemistry

Edited by R. Mannhold, H. Kubinyi, G. Folkers

Editorial Board

H. Buschmann, H. Timmerman, H. van de Waterbeemd

Previous Volumes of this Series:

Urbán, László/Patel, Vinod F./Vaz,
Roy J. (Eds.)

Antitargets and Drug Safety

2015

ISBN: 978-3-527-33511-4

Vol. 66

Keserü, György M./Swinney, David C. (Eds.)

Kinetics and Thermodynamics of Drug Binding

2015

ISBN: 978-3-527-33582-4

Vol. 65

Pfannkuch, Friedlieb/Suter-Dick, Laura (Eds.)

Predictive Toxicology

From Vision to Reality

2014

ISBN: 978-3-527-33608-1

Vol. 64

Kirchmair, Johannes (Ed.)

Drug Metabolism Prediction

2014

ISBN: 978-3-527-33566-4

Vol. 63

Vela, José Miguel/Maldonado, Rafael/Hamon,
Michel (Eds.)

In vivo Models for Drug Discovery

2014

ISBN: 978-3-527-33328-8

Vol. 62

Liras, Spiros/Bell, Andrew S. (Eds.)

Phosphodiesterases and Their Inhibitors

2014

ISBN: 978-3-527-33219-9

Vol. 61

Hanessian, Stephen (Ed.)

Natural Products in Medicinal Chemistry

2014

ISBN: 978-3-527-33218-2

Vol. 60

Lackey, Karen/Roth, Bruce (Eds.)

Medicinal Chemistry Approaches to Personalized Medicine

2013

ISBN: 978-3-527-33394-3

Vol. 59

Brown, Nathan (Ed.)

Scaffold Hopping in Medicinal Chemistry

2013

ISBN: 978-3-527-33364-6

Vol. 58

Hoffmann, Rémy/Gohier, Arnaud/Pospisil,
Pavel (Eds.)

Data Mining in Drug Discovery

2013

ISBN: 978-3-527-32984-7

Vol. 57

Dömling, Alexander (Ed.)

Protein-Protein Interactions in Drug Discovery

2013

ISBN: 978-3-527-33107-9

Vol. 56

Edited by Daniel A. Erlanson and Wolfgang Jahnke

Fragment-based Drug Discovery

Lessons and Outlook

WILEY-VCH
Verlag GmbH & Co. KGaA

Series Editors:

Prof. Dr. Raimund Mannhold

Rosenweg 7
40489 Düsseldorf
Germany
mannhold@uni-duesseldorf.de

Prof. Dr. Hugo Kubinyi

Donnersbergstr. 9
67256 Weisenheim am Sand
Germany
kubinyi@t-online.de

Prof. Dr. Gerd Folkers

Collegium Helveticum
ETH-Zentrum/STW
Schmelzbergstr. 25
8092 Zürich
Switzerland
gerd.folkers@collegium.ethz.ch

Volume Editors:

Dr. Daniel A. Erlanson

Carmot Therapeutics, Inc.
409 Illinois Street
San Francisco, CA 94158
USA

Dr. Wolfgang Jahnke

Novartis Pharma AG
NIBR/DT/PSU
WSJ- 88 904
4002 Basel
Switzerland

All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-33775-0

ePDF ISBN: 978-3-527-68361-1

ePub ISBN: 978-3-527-68362-8

Mobi ISBN: 978-3-527-68363-5

oBook ISBN: 978-3-527-68360-4

Cover Design Grafik-Design Schulz, Fußgönheim, Germany

Typesetting Thomson Digital, Noida, India

Printed on acid-free paper

Contents

Contributors	<i>XV</i>
Preface	<i>XXI</i>
A Personal Foreword	<i>XXIII</i>

Part I The Concept of Fragment-based Drug Discovery 1

1	The Role of Fragment-based Discovery in Lead Finding 3
	<i>Roderick E. Hubbard</i>
1.1	Introduction 3
1.2	What is FBLD? 4
1.3	FBLD: Current Practice 5
1.3.1	Using Fragments: Conventional Targets 5
1.3.2	Using Fragments: Unconventional Targets 13
1.4	What do Fragments Bring to Lead Discovery? 14
1.5	How did We Get Here? 16
1.5.1	Evolution of the Early Ideas and History 16
1.5.2	What has Changed Since the First Book was Published in 2006? 16
1.6	Evolution of the Methods and Their Application Since 2005 19
1.6.1	Developments in Fragment Libraries 21
1.6.2	Fragment Hit Rate and Druggability 22
1.6.3	Developments in Fragment Screening 23
1.6.4	Ways of Evolving Fragments 23
1.6.5	Integrating Fragments Alongside Other Lead-Finding Strategies 23
1.6.6	Fragments Can be Selective 24
1.6.7	Fragment Binding Modes 25
1.6.8	Fragments, Chemical Space, and Novelty 27
1.7	Current Application and Impact 27
1.8	Future Opportunities 28
	References 29

2	Selecting the Right Targets for Fragment-Based Drug Discovery	37
	<i>Thomas G. Davies, Harren Jhoti, Puja Pathuri, and Glyn Williams</i>	
2.1	Introduction	37
2.2	Properties of Targets and Binding Sites	39
2.3	Assessing Druggability	41
2.4	Properties of Ligands and Drugs	42
2.5	Case Studies	43
2.5.1	Case Study 1: Inhibitors of Apoptosis Proteins (IAPs)	44
2.5.2	Case Study 2: HCV-NS3	46
2.5.3	Case Study 3: PKM2	47
2.5.4	Case Study 4: Soluble Adenylate Cyclase	49
2.6	Conclusions	50
	References	51
3	Enumeration of Chemical Fragment Space	57
	<i>Jean-Louis Reymond, Ricardo Visini, and Mahendra Awale</i>	
3.1	Introduction	57
3.2	The Enumeration of Chemical Space	58
3.2.1	Counting and Sampling Approaches	58
3.2.2	Enumeration of the Chemical Universe Database GDB	58
3.2.3	GDB Contents	59
3.3	Using and Understanding GDB	61
3.3.1	Drug Discovery	61
3.3.2	The MQN System	62
3.3.3	Other Fingerprints	63
3.4	Fragments from GDB	65
3.4.1	Fragment Replacement	65
3.4.2	Shape Diversity of GDB Fragments	66
3.4.3	Aromatic Fragments from GDB	68
3.5	Conclusions and Outlook	68
	Acknowledgment	69
	References	69
4	Ligand Efficiency Metrics and their Use in Fragment Optimizations	75
	<i>György G. Ferenczy and György M. Keserű</i>	
4.1	Introduction	75
4.2	Ligand Efficiency	75
4.3	Binding Thermodynamics and Efficiency Indices	78
4.4	Enthalpic Efficiency Indices	81
4.5	Lipophilic Efficiency Indices	83
4.6	Application of Efficiency Indices in Fragment-Based Drug Discovery Programs	88
4.7	Conclusions	94
	References	95

Part II Methods and Approaches for Fragment-based Drug Discovery 99

- 5 Strategies for Fragment Library Design 101**
Justin Bower, Angelo Pugliese, and Martin Drysdale
- 5.1 Introduction 101
 - 5.2 Aims 102
 - 5.3 Progress 102
 - 5.3.1 BDDP Fragment Library Design: Maximizing Diversity 103
 - 5.3.2 Assessing Three-Dimensionality 103
 - 5.3.3 3DFrag Consortium 104
 - 5.3.4 Commercial Fragment Space Analysis 105
 - 5.3.5 BDDP Fragment Library Design 108
 - 5.3.6 Fragment Complexity 111
 - 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules 113
 - 5.4 Future Plans 114
 - 5.5 Summary 116
 - 5.6 Key Achievements 116
 - References 116
- 6 The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery 119**
Ben J. Davis and Anthony M. Giannetti
- 6.1 Introduction 119
 - 6.2 Fragment-Based Lead Discovery on a Difficult Kinase 121
 - 6.3 Application of Orthogonal Biophysical Methods to Identify and Overcome an Unusual Ligand: Protein Interaction 127
 - 6.4 Direct Comparison of Orthogonal Screening Methods Against a Well-Characterized Protein System 131
 - 6.5 Conclusions 135
 - References 136
- 7 Differential Scanning Fluorimetry as Part of a Biophysical Screening Cascade 139**
Duncan E. Scott, Christina Spry, and Chris Abell
- 7.1 Introduction 139
 - 7.2 Theory 140
 - 7.2.1 Equilibria are Temperature Dependent 140
 - 7.2.2 Thermodynamics of Protein Unfolding 142
 - 7.2.3 Exact Mathematical Solutions to Ligand-Induced Thermal Shifts 143
 - 7.2.4 Ligand Binding and Protein Unfolding Thermodynamics Contribute to the Magnitude of Thermal Shifts 145
 - 7.2.5 Ligand Concentration and the Magnitude of Thermal Shifts 147
 - 7.2.6 Models of Protein Unfolding Equilibria and Ligand Binding 148

- 7.2.7 Negative Thermal Shifts and General Confusions 150
- 7.2.8 Lessons Learnt from Theoretical Analysis of DSF 151
- 7.3 Practical Considerations for Applying DSF in Fragment-Based Approaches 152
- 7.4 Application of DSF to Fragment-Based Drug Discovery 154
 - 7.4.1 DSF as a Primary Enrichment Technique 154
 - 7.4.2 DSF Compared with Other Hit Identification Techniques 159
 - 7.4.3 Pursuing Destabilizing Fragment Hits 166
 - 7.4.4 Lessons Learnt from Literature Examples of DSF in Fragment-Based Drug Discovery 168
- 7.5 Concluding Remarks 169
 - Acknowledgments 169
 - References 170

8 Emerging Technologies for Fragment Screening 173

Sten Ohlson and Minh-Dao Duong-Thi

- 8.1 Introduction 173
- 8.2 Emerging Technologies 175
 - 8.2.1 Weak Affinity Chromatography 175
 - 8.2.1.1 Introduction 175
 - 8.2.1.2 Theory 177
 - 8.2.1.3 Fragment Screening 179
 - 8.2.2 Mass Spectrometry 185
 - 8.2.2.1 Introduction 185
 - 8.2.2.2 Theory 186
 - 8.2.2.3 Applications 186
 - 8.2.3 Microscale Thermophoresis 187
 - 8.2.3.1 Introduction 187
 - 8.2.3.2 Theory 189
 - 8.2.3.3 Applications 189
- 8.3 Conclusions 189
 - Acknowledgments 191
 - References 191

9 Computational Methods to Support Fragment-based Drug Discovery 197

Laurie E. Grove, Sandor Vajda, and Dima Kozakov

- 9.1 Computational Aspects of FBDD 197
- 9.2 Detection of Ligand Binding Sites and Binding Hot Spots 198
 - 9.2.1 Geometry-based Methods 199
 - 9.2.2 Energy-based Methods 201
 - 9.2.3 Evolutionary and Structure-based Methods 202
 - 9.2.4 Combination Methods 202
- 9.3 Assessment of Druggability 203
- 9.4 Generation of Fragment Libraries 205

9.4.1	Known Drugs	206
9.4.2	Natural Compounds	207
9.4.3	Novel Scaffolds	208
9.5	Docking Fragments and Scoring	209
9.5.1	Challenges of Fragment Docking	209
9.5.2	Examples of Fragment Docking	210
9.6	Expansion of Fragments	212
9.7	Outlook	214
	References	214
10	Making FBDD Work in Academia	223
	<i>Stacie L. Bulfer, Frantz Jean-Francois, and Michelle R. Arkin</i>	
10.1	Introduction	223
10.2	How Academic and Industry Drug Discovery Efforts Differ	225
10.3	The Making of a Good Academic FBDD Project	226
10.4	FBDD Techniques Currently Used in Academia	228
10.4.1	Nuclear Magnetic Resonance	229
10.4.2	X-Ray Crystallography	230
10.4.3	Surface Plasmon Resonance/Biolayer Interferometry	231
10.4.4	Differential Scanning Fluorimetry	232
10.4.5	Isothermal Titration Calorimetry	232
10.4.6	Virtual Screening	232
10.4.7	Mass Spectrometry	233
10.4.7.1	Native MS	233
10.4.7.2	Site-Directed Disulfide Trapping (Tethering)	234
10.4.8	High-Concentration Bioassays	234
10.5	Project Structures for Doing FBDD in Academia	235
10.5.1	Targeting p97: A Chemical Biology Consortium Project	235
10.5.2	Targeting Caspase-6: An Academic–Industry Partnership	236
10.6	Conclusions and Perspectives	239
	References	240
11	Site-Directed Fragment Discovery for Allostery	247
	<i>T. Justin Rettenmaier, Sean A. Hudson, and James A. Wells</i>	
11.1	Introduction	247
11.2	Caspases	249
11.2.1	Tethered Allosteric Inhibitors of Executioner Caspases-3 and -7	249
11.2.2	Tethering Inflammatory Caspase-1	250
11.2.3	Tethered Allosteric Inhibitors of Caspase-5	251
11.2.4	General Allosteric Regulation at the Caspase Dimer Interface	252
11.2.5	Using Disulfide Fragments as “Chemi-Locks” to Generate Conformation-Specific Antibodies	253
11.3	Tethering K-Ras(G12C)	254
11.4	The Master Transcriptional Coactivator CREB Binding Protein	256

11.4.1	Tethering to Find Stabilizers of the KIX Domain of CBP	256
11.4.2	Dissecting the Allosteric Coupling between Binding Sites on KIX	257
11.4.3	Rapid Identification of pKID-Competitive Fragments for KIX	258
11.5	Tethering Against the PIF Pocket of Phosphoinositide-Dependent Kinase 1 (PDK1)	259
11.6	Tethering Against GPCRs: Complement 5A Receptor	261
11.7	Conclusions and Future Directions	263
	References	264
12	Fragment Screening in Complex Systems	267
	<i>Miles Congreve and John A. Christopher</i>	
12.1	Introduction	267
12.2	Fragment Screening and Detection of Fragment Hits	268
12.2.1	Fragment Screening Using NMR Techniques	270
12.2.2	Fragment Screening Using Surface Plasmon Resonance	271
12.2.3	Fragment Screening Using Capillary Electrophoresis	272
12.2.4	Fragment Screening Using Radioligand and Fluorescence-Based Binding Assays	273
12.2.5	Ion Channel Fragment Screening	275
12.3	Validating Fragment Hits	276
12.4	Fragment to Hit	279
12.4.1	Fragment Evolution	280
12.4.2	Fragment Linking	281
12.5	Fragment to Lead Approaches	281
12.5.1	Fragment Evolution	282
12.5.2	Fragment Linking	284
12.6	Perspective and Conclusions	285
	Acknowledgments	287
	References	287
13	Protein-Templated Fragment Ligation Methods: Emerging Technologies in Fragment-Based Drug Discovery	293
	<i>Mike Jaegle, Eric Nawrotzky, Ee Lin Wong, Christoph Arkona, and Jörg Rademann</i>	
13.1	Introduction: Challenges and Visions in Fragment-Based Drug Discovery	293
13.2	Target-Guided Fragment Ligation: Concepts and Definitions	294
13.3	Reversible Fragment Ligation	295
13.3.1	Dynamic Reversible Fragment Ligation Strategies	295
13.3.2	Chemical Reactions Used in Dynamic Fragment Ligations	296
13.3.3	Detection Strategies in Dynamic Fragment Ligations	299
13.3.4	Applications of Dynamic Fragment Ligations in FBDD	301
13.4	Irreversible Fragment Ligation	311
13.4.1	Irreversible Fragment Ligation Strategies: Pros and Cons	311

- 13.4.2 Detection in Irreversible Fragment Ligation 311
- 13.4.3 Applications of Irreversible Fragment Ligations in FBDD 313
- 13.5 Fragment Ligations Involving Covalent Reactions with Proteins 316
- 13.6 Conclusions and Future Outlook: How Far did We Get and What will be Possible? 319
- References 320

Part III Successes from Fragment-based Drug Discovery 327

14 BACE Inhibitors 329

Daniel F. Wyss, Jared N. Cumming, Corey O. Strickland, and Andrew W. Stamford

- 14.1 Introduction 329
- 14.2 FBDD Efforts on BACE1 333
 - 14.2.1 Fragment Hit Identification, Validation, and Expansion 333
 - 14.2.2 Fragment Optimization 333
 - 14.2.3 From a Key Pharmacophore to Clinical Candidates 340
- 14.3 Conclusions 346
- References 346

15 Epigenetics and Fragment-Based Drug Discovery 355

Aman Iqbal and Peter J. Brown

- 15.1 Introduction 355
- 15.2 Epigenetic Families and Drug Targets 357
- 15.3 Epigenetics Drug Discovery Approaches and Challenges 358
- 15.4 FBDD Case Studies 359
 - 15.4.1 BRD4 (Bromodomain) 360
 - 15.4.2 EP300 (Bromodomain) 363
 - 15.4.3 ATAD2 (Bromodomain) 364
 - 15.4.4 BAZ2B (Bromodomain) 364
 - 15.4.5 SIRT2 (Histone Deacetylase) 365
 - 15.4.6 Next-Generation Epigenetic Targets: The “Royal Family” and Histone Demethylases 366
- 15.5 Conclusions 367
- Abbreviations 368
- References 368

16 Discovery of Inhibitors of Protein–Protein Interactions Using Fragment-Based Methods 371

Feng Wang and Stephen W. Fesik

- 16.1 Introduction 371
- 16.2 Fragment-Based Strategies for Targeting PPIs 372
 - 16.2.1 Fragment Library Construction 372
 - 16.2.2 NMR-Based Fragment Screening Methods 373

- 16.2.3 Structure Determination of Complexes 374
- 16.2.4 Structure-Guided Hit-to-Lead Optimization 375
- 16.3 Recent Examples from Our Laboratory 376
 - 16.3.1 Discovery of RPA Inhibitors 377
 - 16.3.2 Discovery of Potent Mcl-1 Inhibitors 378
 - 16.3.3 Discovery of Small Molecules that Bind to K-Ras 379
- 16.4 Summary and Conclusions 382
 - Acknowledgments 383
 - References 384

- 17 Fragment-Based Discovery of Inhibitors of Lactate Dehydrogenase A 391**
 - Alexander L. Breeze, Richard A. Ward, and Jon Winter*
 - 17.1 Aerobic Glycolysis, Lactate Metabolism, and Cancer 391
 - 17.2 Lactate Dehydrogenase as a Cancer Target 392
 - 17.3 “Ligandability” Characteristics of the Cofactor and Substrate Binding Sites in LDHA 394
 - 17.4 Previously Reported LDH Inhibitors 395
 - 17.5 Fragment-Based Approach to LDHA Inhibition at AstraZeneca 398
 - 17.5.1 High-Throughput Screening Against LDHA 398
 - 17.5.2 Rationale and Strategy for Exploration of Fragment-Based Approaches 399
 - 17.5.3 Development of Our Biophysical and Structural Biology Platform 400
 - 17.5.4 Elaboration of Adenine Pocket Fragments 404
 - 17.5.5 Screening for Fragments Binding in the Substrate and Nicotinamide Pockets 405
 - 17.5.6 Reaching out Across the Void 407
 - 17.5.7 Fragment Linking and Optimization 408
 - 17.6 Fragment-Based LDHA Inhibitors from Other Groups 410
 - 17.6.1 Nottingham 410
 - 17.6.2 Ariad 413
 - 17.7 Conclusions and Future Perspectives 417
 - References 419

- 18 FBDD Applications to Kinase Drug Hunting 425**
 - Gordon Saxty*
 - 18.1 Introduction 425
 - 18.2 Virtual Screening and X-ray for PI3K 426
 - 18.3 High-Concentration Screening and X-ray for Rock1/2 427
 - 18.4 Surface Plasmon Resonance for MAP4K4 428
 - 18.5 Weak Affinity Chromatography for GAK 429
 - 18.6 X-ray for CDK 4/6 430
 - 18.7 High-Concentration Screening, Thermal Shift, and X-ray for CHK2 432
 - 18.8 Virtual Screening and Computational Modeling for AMPK 433
 - 18.9 High-Concentration Screening, NMR, and X-ray FBDD for PDK1 434

18.10	Tethering Mass Spectrometry and X-ray for PDK1	435
18.11	NMR and X-ray Case Study for Abl (Allosteric)	436
18.12	Review of Current Kinase IND's and Conclusions	437
	References	442
19	An Integrated Approach for Fragment-Based Lead Discovery: Virtual, NMR, and High-Throughput Screening Combined with Structure-Guided Design. Application to the Aspartyl Protease Renin.	447
	<i>Simon Rüdisser, Eric Vangrevelinghe, and Jürgen Maibaum</i>	
19.1	Introduction	447
19.2	Renin as a Drug Target	449
19.3	The Catalytic Mechanism of Renin	451
19.4	Virtual Screening	452
19.5	Fragment-Based Lead Finding Applied to Renin and Other Aspartyl Proteases	455
19.6	Renin Fragment Library Design	464
19.7	Fragment Screening by NMR T ₁ ρ Ligand Observation	469
19.8	X-Ray Crystallography	473
19.9	Renin Fragment Hit-to-Lead Evolution	475
19.10	Integration of Fragment Hits and HTS Hits	476
19.11	Conclusions	479
	References	480
	Index	487

Contributors

Chris Abell

University of Cambridge
Department of Chemistry
Lensfield Road
Cambridge
CB2 1EW
UK

Michelle R. Arkin

University of California, San
Francisco
School of Pharmacy
Small Molecule Discovery Center

and

Department of Pharmaceutical
Chemistry
UCSF Mission Bay Campus
1700 4th Street
San Francisco
CA 94158
USA

Christoph Arkona

Freie Universität Berlin
Institut für Pharmazie
Königin-Luise-Str. 2 +4
14195 Berlin
Germany

Mahendra Awale

University of Berne
Department of Chemistry and
Biochemistry
Freiestrasse 3
3012 Berne
Switzerland

Justin Bower

Cancer Research UK Beatson
Institute
Garscube Estate
Switchback Road
Bearsden
Glasgow
G61 1BD
UK

Alexander L. Breeze

AstraZeneca R&D
Discovery Sciences
Alderley Park
Macclesfield
SK10 4TG
UK

and

University of Leeds
Astbury Centre for Structural
Molecular Biology
Faculty of Biological Sciences
Leeds
LS2 9JT
UK

Peter J. Brown

2 Structural Genomics Consortium
7th Floor, MaRS South Tower
101 College Street
Toronto
ON M5G 1L7
Canada

Stacie L. Bulfer

University of California, San
Francisco
School of Pharmacy
Small Molecule Discovery Center

and

Department of Pharmaceutical
Chemistry
UCSF Mission Bay Campus
1700 4th Street
San Francisco
CA 94158
USA

John A. Christopher

Heptares Therapeutics Ltd
BioPark, Broadwater Road
Welwyn Garden City
AL73AX
UK

Miles Congreve

Heptares Therapeutics Ltd
BioPark, Broadwater Road
Welwyn Garden City
AL73AX
UK

Jared N. Cumming

Merck Research Laboratories
Structural Chemistry
2015 Galloping Hill Road
Kenilworth
NJ 07033
USA

Thomas G. Davies

Astex Pharmaceuticals
436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
UK

Ben J. Davis

Vernalis Research
Granta Park
Cambridge
CB21 6GB
UK

Martin Drysdale

Cancer Research UK Beatson
Institute
Garscube Estate
Switchback Road
Bearsden
Glasgow
G61 1BD
UK

Minh-Dao Duong-Thi

Nanyang Technological University
School of Biological Sciences
60 Nanyang Drive
637551
Singapore

György G. Ferenczy

Hungarian Academy of Sciences
Research Center for Natural
Sciences
Magyar tudósok krt. 2
H-1117 Budapest
Hungary

Stephen W. Fesik

Professor of Biochemistry
Pharmacology and Chemistry
Vanderbilt University School of
Medicine
2215 Garland Ave.
607 Light Hall
Nashville
TN 37232-0146
USA

Anthony M. Giannetti

Google[x]
1600 Amphitheatre Parkway
Mountain View
CA 94043
USA

Laurie E. Grove

Wentworth Institute of Technology
Department of Sciences
Boston
MA 02115
USA

Roderick E. Hubbard

Vernalis Research
Granta Park, Cambridge
CB21 6GB
UK

and

YSBL
University of York
Heslington, York
YO10 5DD
UK

Sean A. Hudson

University of California, San
Francisco
Department of Pharmaceutical
Chemistry
UCSF Mission Bay Campus
1700 4th Street
San Francisco
CA 94158
USA

Aman Iqbal

Proteorex Therapeutics Inc.
40 King Street West
Toronto
ON M5H 3Y4
Canada

Mike Jaegle

Freie Universität Berlin
Institut für Pharmazie
Königin-Luise-Str. 2 + 4
14195 Berlin
Germany

Frantz Jean-Francois

University of California, San
Francisco
School of Pharmacy
Small Molecule Discovery Center

and

Department of Pharmaceutical
Chemistry
UCSF Mission Bay Campus
1700 4th Street
San Francisco
CA 94158
USA

Harren Jhoti

Astex Pharmaceuticals
436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
UK

György M. Keserü

Hungarian Academy of Sciences
Research Center for Natural
Sciences
Magyar tudósok krt. 2
H-1117 Budapest
Hungary

Dima Kozakov

Boston University
Department of Biomedical
Engineering
Boston
MA 02215
USA

Jürgen Maibaum

Novartis Pharma AG
Novartis Institutes for Biomedical
Research
Novartis Campus
4002 Basel
Switzerland

Eric Nawroitzky

Freie Universität Berlin
Institut für Pharmazie
Königin-Luise-Str. 2 + 4
14195 Berlin
Germany

Sten Ohlson

Nanyang Technological University
School of Biological Sciences
60 Nanyang Drive
Singapore 637551
Singapore

Puja Pathuri

Astex Pharmaceuticals
436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
UK

Angelo Pugliese

Cancer Research UK Beatson
Institute
Garscube Estate
Switchback Road
Bearsden
Glasgow
G61 1BD
UK

Jörg Rademann

Freie Universität Berlin
Institut für Pharmazie
Königin-Luise-Str. 2 + 4
14195 Berlin
Germany

T. Justin Rettenmaier

University of California, San
Francisco
Department of Pharmaceutical
Chemistry
UCSF Mission Bay Campus
1700 4th Street
San Francisco
CA 94158
USA

Jean-Louis Reymond

University of Berne
Department of Chemistry and
Biochemistry
Freiestrasse 3
3012 Berne
Switzerland

Simon Rüdisser

Novartis Pharma AG
Novartis Institutes for Biomedical
Research
Novartis Campus
4002 Basel
Switzerland

Gordon Saxty

Fidelta Ltd.
Prilaz baruna Filipovića 29
10000 Zagreb
Croatia

Duncan E. Scott

University of Cambridge
Department of Chemistry
Lensfield Road
Cambridge
CB2 1EW
UK

Christina Spry

University of Cambridge
Department of Chemistry
Lensfield Road
Cambridge
CB2 1EW
UK

and

The Australian National University
Research School of Biology
Linnaeus Way
Canberra
ACT 2601
Australia

Andrew W. Stamford

Merck Research Laboratories
126 East Lincoln Avenue
Rahway
NJ 07065
USA

Corey O. Strickland

Merck Research Laboratories
Structural Chemistry
2015 Galloping Hill Road
Kenilworth
NJ 07033
USA

Sandor Vajda

Boston University
Department of Biomedical
Engineering and
Department of Chemistry
Boston
MA 02215
USA

Eric Vangrevelinghe

Novartis Pharma AG
Novartis Institutes for Biomedical
Research
Novartis Campus
4002 Basel
Switzerland

Ricardo Visini

University of Berne
Department of Chemistry and
Biochemistry
Freiestrasse 3
3012 Berne
Switzerland

Feng Wang

Vanderbilt University School of
Medicine
Department of Biochemistry
2200 Pierce Ave.
802/804 RRB
Nashville
TN 37232-0146
USA

Richard A. Ward

AstraZeneca R&D
Oncology iMED
Alderley Park
Macclesfield
SK10 4TG
UK

James A. Wells

University of California, San
Francisco
Department of Pharmaceutical
Chemistry
UCSF Mission Bay Campus
1700 4th Street
San Francisco
CA 94158
USA

Glyn Williams

Astex Pharmaceuticals
436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
UK

Jon Winter

AstraZeneca R&D
Oncology iMED
Alderley Park
Macclesfield
SK10 4TG
UK

Ee Lin Wong

Freie Universität Berlin
Institut für Pharmazie
Königin-Luise-Str. 2 + 4
14195 Berlin
Germany

Daniel F. Wyss

Merck Research Laboratories
Structural Chemistry
2015 Galloping Hill Road
Kenilworth
NJ 07033
USA

Preface

Just two decades ago, Stephen Fesik initiated fragment-based ligand design by developing an NMR-based method to search for small, low-affinity ligands in adjacent binding pockets of a protein and to link them to a high-affinity ligand [1]. A broader use of this approach was hindered both by its limitation to relatively small proteins and by a patent application. However, within short time alternative methods emerged, originally based on different NMR techniques, later using protein crystallography. Thus, structure-based design was not any longer restricted to “large” molecules: libraries of much smaller fragment-type compounds were tested experimentally or screened *in silico*, with the advantage that a small ligand has a much better chance to fit a certain binding site. In further steps, the ligand can grow into the environment of its pocket or can be linked to an adjacent fragment. The only critical step in fragment combination is the search for a linker that combines the fragments in a relaxed, bioactive conformation, optimally stabilizing this favorable conformation.

Ten years later, in 2006, time was already ripe to review the techniques and the accumulated experience in fragment-based ligand design: Wolfgang Jahnke and Daniel Erlanson edited the very first book on this topic [2]. Now, another 10 years later, the discipline has significantly developed and a major number of drug candidates resulted from its use. Thus, we are very grateful that both experts agreed to edit not only a new edition but also a completely new book on fragment-based design. In its introductory section, leading scientists of this area review the role of fragment-based approaches in lead finding and the selection of appropriate targets. Next, an overview on chemical space is provided. The second section discusses library design and various screening techniques, together with a major number of issues that are relevant in fragment-based ligand discovery. The last section presents a significant number of success stories, providing evidence for the broad applicability of fragment-based design in drug research.

As last time, we are very grateful to the editors Daniel Erlanson and Wolfgang Jahnke for assembling such a unique collection of important topics, as well as to all chapter authors for their excellent work. Last but not least we thank the

publisher Wiley-VCH, in particular Waltraud Wüst and Frank Weinreich, for their valuable contributions to this project and the entire series.

Düsseldorf
Weisenheim am Sand
Zürich

Raimund Mannhold
Hugo Kubinyi
Gerd Folkers

October 2015

Reference

- 1 Shuker, S.B., Hajduk, P.J., Meadows, R.P. and Fesik, S.W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. *Science*, **274**, 1531–1534.
- 2 Jahnke, W. and Erlanson, D. eds., (2006) *Fragment-based Approaches in Drug Discovery* (Volume 34 of *Methods and Principles in Medicinal Chemistry*, eds.), R. Mannhold, H. Kubinyi, and G. Folkers Wiley-VCH Verlag GmbH, Weinheim.

A Personal Foreword


For the great things are not done by impulse, but by a series of small things brought together.

Vincent Van Gogh, 1888

When Wiley-VCH asked us whether we would be willing to edit a new book on fragment-based drug discovery, our first reaction was panic. Editing a book is a daunting task, and having done it once already we knew well what was in store.

Our second reaction was to ask whether a new book was really needed. Since the very first book on fragment-based drug discovery was published by Wiley-VCH in 2006, six more books have appeared, along with dedicated journal issues and dozens of reviews. Was there anything new to say?

Happily, as you will soon discover, the answer is an emphatic yes! This is clearly illustrated by a search for publications containing the phrase “fragment-based drug discovery” in SciFinder[®], as seen in the figure.



(*2015 numbers through August 25 only)

The past few years have seen a bumper crop of papers on the topic, and given that this search was run in August of 2015 this trend looks set to continue if not

accelerate. From its origins as a niche technique, fragment-based approaches have spread throughout the world to organizations large and small and are embraced by biologists, biophysicists, chemists, modelers, and more. More than 30 drugs derived from fragments have entered the clinic (<http://practicalfragments.blogspot.com/2015/01/fragments-in-clinic-2015-edition.html>), and one (vemurafenib) has already been approved. This book is a comprehensive view of where the field stands – and where it is going.

We would like to thank Wiley-VCH, especially Frank Weinreich and Waltraud Wüst, for encouraging us to undertake this project and patiently working with us through the inevitable but nonetheless frustrating difficulties and delays. We would also like to thank our contributors, all of whom are extraordinarily busy and accomplished scientists. We are thrilled with the response we received to our invitations and with the depth and quality of the chapters. Finally, we would like to thank you for reading. We hope that you will find something useful to apply to your own research: each of our fragmentary efforts advances the great human enterprise of drug discovery.

San Francisco
Basel
August 2015

*Daniel A. Erlanson
Wolfgang Jahnke*

Part I
The Concept of Fragment-based Drug Discovery

1

The Role of Fragment-based Discovery in Lead Finding

Roderick E. Hubbard

1.1

Introduction

Fragment-based lead discovery (FBLD) is now firmly established as a mature collection of methods and approaches for the discovery of small molecules that bind to protein or nucleic acid targets. The approach is being successfully applied in the search for new drugs, with many compounds now in clinical trials (see summary in [1]) and with the first fragment-derived compound now treating patients [2]. The approach has also had a number of other impacts such as providing starting points for lead discovery for challenging, unconventional targets such as protein–protein interactions [3–5], increasing the use of biophysics to characterize compound binding and properties, and providing small groups, particularly in academia, with access to the tools to identify chemical probes of biological systems [6,7].

The other chapters in this book will discuss the details and new advances in the methods and provide examples of how fragments have been used in specific projects. In this chapter, I will draw on my own experiences and view of the literature to discuss three main areas. First, I will review current practice in FBLD, highlighting how and when fragments have an impact on the drug discovery process. Second, I will then review how the ideas have developed, with particular emphasis on the past 10 years. I will discuss how fragment methods and thinking have been extended and refined and how these developments have affected the lead discovery process in drug discovery. Finally, I will discuss some of the areas where we can see that improvements in fragment methods could have further impact on discovery.

The discussion will focus on fragment-based discovery against protein targets. Although there are a few examples of fragments being used against RNA [8–10] and DNA [11] targets, the majority of reported campaigns are against proteins. Two types of protein target will be considered. The first shall be called conventional targets. These are proteins such as kinases where although it is never straightforward to achieve the required selectivity and balance of physicochemical properties in the compound, the proteins usually behave in most of the

experiments and assays. Crystal structures are usually readily obtained, large amounts of pure, homogeneous, and functional proteins can be generated for biophysical studies, and the activity assays are robust and well understood. The second class of target shall be called unconventional targets. There are two types here – the first are protein–protein interaction targets such as the proapoptotic Bcl-2 family or Ras, where experience over the years has eventually established reasonably robust assays and although crystal structures take some time to determine and the protein does not always behave in biophysical assays, it is possible to establish structure-based discovery. The main challenge here is the nature of the binding sites, with often large, hydrophobic, and sometimes flexible sites. The second type of unconventional targets are the results of recent advances in our understanding of mammalian disease biology and consist of new classes of enzymes (such as the ubiquitin processing machinery [12]), disrupting multiprotein complexes, and proteins that are intrinsically disordered in some way (such as the one described in [13]). Here, the primary challenges are often in producing sufficient, homogeneous, functional protein for study, knowing what the post-translational modification state or even which complex is the true target and establishing robust assays to report on activity or binding. This last issue is often not appreciated – it can take a long time to establish the assays on new classes of target, not only because there is intrinsic variability in the behavior of the system but also because there is often not a tool compound available with which to validate the assay.

1.2

What is FBLD?

There are two distinctive features of fragment-based discovery compared to other approaches to lead finding. The first is that the discovery process begins with screening a small (usually 1–2000 member) library of low molecular weight (typically less than 20 heavy atom) compounds for binding to a particular site on the target. Key is the molecular weight of the fragments – they are big enough to probe interactions in the protein but small enough to minimize chances of unfavorable interactions. The second distinctive feature lies in the approach to optimizing these hits to lead compounds, either through careful, usually structure-guided, growth of the fragment or through merging information from fragments and elsewhere to generate optimized hits.

In many ways, fragments can be viewed as a state of mind – an approach to use the fragments as chemical tools to dissect what the requirements are for the chemical matter that affects a particular target in the desired way (affinity, selectivity) and using a combination of rational, usually structure-guided, and often biophysics-based methods for generation of the optimized compounds. We can define a fragment approach as one of intent – and that intent affects the strategy, methods, and thinking that is applied during the early parts of a discovery project. Detection and characterization of such weakly binding compounds can be

problematic for some classes of target, with concerns over false positive and false negative hits, changes in binding mode, and so on. So, fragment methods engender a questioning, problem-solving approach to research. This is carried through into the usually structure-guided evolution of the initial fragment hits, which allows careful assembly of compounds that bind with high efficiency combined with suitable compound properties.

1.3

FBLD: Current Practice

Figure 1.1 and its legend summarize the contemporary approach to fragment-based discovery followed by most practitioners. There are five main components to a fragment platform: a fragment library, a method for finding which fragments bind, characterizing how the fragments bind by determining structure and biophysical measurements, exploring fragment SAR to identify the best fragment(s) to progress, and using the fragment(s) to generate lead compounds. Figure 1.1 also emphasizes how information about binding motifs is combined with information from HTS hits, literature compounds, or virtual screening hits. Other chapters in this book will provide detail on each of these different areas. In this chapter, I am focusing on the impact fragments have had on the lead discovery process. This is best done with some examples.

1.3.1

Using Fragments: Conventional Targets

Conventional targets are ones with well-defined active sites (such as most enzymes) where structural information is readily available. It is usual to get a large number of fragment hits for such targets – at Vernalis our experience has been 50–150 validated hits from screening a library of about 1500 fragments [14,15]. A lower hit rate can indicate there may be issues with progressing compounds against the target as discussed later. Modeling of the binding of these fragments can be helpful, but the most effective fragment to hit to lead optimization campaigns uses the detailed information available from experimental structures determined by X-ray crystallography (preferred) or if necessary by NMR. The main issue with NMR is the time it takes to generate structures. A suitable crystal form can generate many hundreds of crystal structures during the early months of a project, whereas it takes at best a few days for NMR methods to generate models for binding. In addition, NMR models rarely have the resolution to give confidence in some of the subtleties of binding mode necessary for design of selective compounds (such as for kinases).

The three main ways of using fragments are growing, merging, and linking. Figure 1.2a–c shows some representative examples that we can use to describe the essential features of each approach.




Figure 1.1 the FBLD process. There are five main components to a fragment platform. (a) Fragment library: there is an extensive literature on the design of fragment libraries [26,31,32,41]. The choice of compounds is constrained both by the demands of the screening methods (solubility, detection) and by the need to evolve the compounds (elaboration vectors, synthetic tractability) as well as avoiding reactive or toxic substructures. Key is the number of heavy atoms in the compounds. Analyses by Reymond [38,39] suggest that the number of possible lead-like compounds (chemical space) increases by around eightfold for each heavy atom. There are many approximations but this means that a fragment library of 1000 compounds of average MW 190 is equivalent to 10^8 compounds of MW 280 and 10^{18} compounds of MW 450. (b) Fragment screening: Table 1.1 summarizes the experiences at Vernalis over the years that are variously described elsewhere [15]. For all techniques, the main limitations are whether the protein target can be prepared in a suitable format for screening and whether the fragments are sufficiently soluble. The most robust method of screening is ligand-observed NMR, which has the

dynamic range (typically from 5 mM to 100 nM) seen for fragment binding and particularly important for unconventional targets, as the integrity of the ligand and protein is checked at each experiment. (c) Characterizing fragment binding: for conventional targets, it is often possible to rapidly determine crystal structures of the fragment binding to the protein and, if the biochemical or binding assay is not suitable, use a biophysical method to validate and if possible quantify potency. For unconventional targets, this step is particularly important as the targets can have challenging binding sites, where conformational flexibility or large hydrophobic surfaces can challenge reliable detection of fragment binding. NMR methods can be used for unconventional targets, ranging from binding site localization (HSQC) to NMR-guided models (measuring NOE distances from ligand atoms to protein residues) and full structure determination. These are constrained by the size of the protein and requirement for isotope labeling. (d) Fragment SAR and optimization: there are two well-established methods – (1) SAR by catalog where features of the fragment are used to identify commercially available compounds for purchase and assay and

Table 1.1 A summary of the characteristics of the most widely used fragment screening methods.

Method	Sensitivity	Issues
Ligand-observed NMR – a number of NMR experiments (STD [82], Water-Logsy [83], and CPMG [84]) detect binding of a ligand to the protein	10 mM– 100 nM	Requires large amounts of protein (many 10 s mgs) but the most robust method for detecting weak binding. Each experiment confirms that the ligand and protein maintain their integrity in solution; the use of a competitor ligand to displace the fragment can identify nonspecific binding. These features make the technique particularly suitable for weak binding to challenging targets. Requires careful design to identify allosteric or cryptic binding sites
Protein-observed NMR – HSQC experiment detects changes in the local environment of ^{15}N or ^{13}C nuclei as ligand added	5 mM– 100 nM	Requires isotopic labeling of the protein; limited to proteins <35 kDa; can titrate ligand onto protein and determine K_D ; pattern of changes in spectra can confirm the same binding site for different ligands and identify allosteric sites; assignment of spectrum allows localization of site
X-ray crystallography: either cocrystallization (crystals formed from the preformed protein–ligand complex) or soaking (high concentrations of ligand added to apo crystals)	All affinities	Cocrystallization can require different crystal conditions for each ligand. Soaking of apo crystals requires crystal form with accessible protein binding site; depending on crystal form can identify cryptic sites Crystal structure provides information-rich description of protein–ligand interactions ready for design
Surface plasmon resonance [47]; monitor molecular weight change as one component flows past the other attached to a surface	500 μM lower limit	Two modes – direct binding (protein attached, ligand flows) allows kinetics (k_{on} and k_{off}) to be measured; indirect, or affinity in solution, where tool compound attached and protein (in the presence of possible fragment) is flowed past. Main issue is immobilization and integrity of protein on surface

(continued)

(2) detailed design of bespoke compounds to optimize the fragment itself and explore potential vectors for elaboration. More recently, there have been new methods such as off-rate screening [16] that allow rapid profiling of compounds where substituents have been added to particular positions on the fragment, prospecting for suitable vectors for

fragment evolution. This can be particularly important when limited structural information is available. (e) Fragment to candidate: medicinal chemistry optimization, supported where possible by rapid crystal structure determination, to bring together information from the portfolio of fragments, hits, HTS, literature, and so on to design and optimize lead compounds.

Table 1.1 (Continued)

Method	Sensitivity	Issues
Enzyme/binding assays	100 μ M lower limit usually	The high concentrations of ligand interfere with most formats of assay preventing detection of mM binding fragments; effective for some assay formats and for well-defined active sites – for example, kinases
Isothermal titration calorimetry (ITC) [85]	1 mM–10 nM	Requires too much protein and ligand to be useful for screening, but the most robust method for measuring K_D as long as the interaction involves a change in ΔH
Mass spectrometry	100 μ M	Requires protein/buffer system that “flies” in the mass spectrometer and an interaction that can survive in the gas phase. Effective for covalent interactions –too variable for weakly binding fragments
Weak-affinity chromatography [51] – immobilize the target on a silica column, then use LC–MS to identify retained ligands	1 μ M upper limit	A cheap way of measuring weak interactions (using simple LC–MS equipment). As for SPR, the main limitation is attachment of protein to surface and behavior of the fragments on the surface
Thermal shift analysis (TSA) [86] – measure the melting temperature of the target by monitoring the increase in fluorescence as the target is heated up in the presence of a dye plus and minus the ligand	500 μ M lower limit	A relatively reliable technique for detecting binding of ligands that bind better than 10 μ M, but many false positives and negatives in detecting fragment binding – the change in melting temperature is too small to measure. Uses small amounts of material and inexpensive instrumentation

Fragment linking is a conceptually very attractive idea – find two fragments that bind in adjacent sites and achieve a high-affinity compound by linking them together. This was the basis of the initial SAR by NMR approach, but with a few exceptions, only the Abbott group (such as summarized in Figure 1.2a, see also Table 1.3), and the follow-on work by Fesik at Vanderbilt (see later), has




Figure 1.2 (a) Evolving fragments – linking. The SAR by NMR approach was developed by the Abbott group in the 1990s [22] (see also the reviews [63,64]). Protein-observed NMR screening of a library identifies the first site binder (screen 1) that can then be optimized (optimize 1). The second screen (screen 2) is then performed in the presence of an excess of the optimized first site binder to identify the second site binder that can also be optimized (optimize 2). NMR structure determination identifies appropriate vectors for linking the two fragments (link) to give a compound that can then be optimized. The first disclosed example was for FKBP [22]; the first drug discovery project was on stromelysin [65] and arguably the most successful was for the Bcl-2 family of proteins [66–69]. For stromelysin, compound 1 was not from screening but is a known metalloprotease binding motif. Screening in the presence of 1 identified compounds such as 2 that after




Figure 1.2 (a) (Continued) optimization gave 3. Combining these in 4 very neatly demonstrates the power of the method – a large increase in potency, clearly retaining the two weakly binding fragments. For the Bcl-2 family, the evolution from the two site binding fragments 5 and 6 is less obvious in compound 7, although the method did provide starting points for chemistry where conventional HTS failed. A considerable amount of medicinal chemistry optimization was needed to generate ABT-737 [66] that briefly entered

clinical trials, followed by ABT-263 [70] with better drug-like properties though still with a dual Bcl-2/Bcl-x_L profile that can give undesired pharmacology. This has recently been succeeded in the clinic by the more Bcl-2 selective ABT-199 [71]. With few exceptions [72], the continued champion of the linking approach is Fesik, now at Vanderbilt (see Figure 1.2d). Most other practitioners find it difficult to identify such multiple sites and commit such dedicated chemistry resources to a linking strategy.